Your privacy is important to us, so we operate the site by the following principles:

Confidentiality
You may use our site without disclosing personally identifiable information. We want to be clear that we will not obtain such information about you unless you choose to submit it to us. If you supply personally identifiable information (such as name, address or telephone numbers) for various purposes on this site, we only use the information for that purpose (such as to provide the service or information you have requested).

Security
The Dana-Farber Waldenstrom's Macroglobulinemia Program takes every precaution to protect our users' information. When a registration/order form asks users to enter sensitive information (such as credit card number and/or diagnosis), that information is encrypted and is protected with the best encryption software in the industry- SSL.

Should you electronically request a referral to a Dana-Farber physician, we will use the information you submit to arrange for care where appropriate. While we use SSL encryption to protect sensitive information online, we also do everything in our power to protect user-information off line. Our software and hardware is configured to provide maximum security.

To use our contact form, the Magic Word is Bing.

Cookies
The Dana-Farber Waldenstrom's Macroglobulinemia Program Web sites use cookies to track traffic coming to our site. We do not collect personal data such as name, age, phone number, e-mail, or mailing address. Cookies will also be used to identify a person who chooses to register on our site. If you choose to register on our site and are given a password for an event, give donations on line, or choose to enroll in our e-mail subscription services, we will identify you with cookies. You will always have a chance to opt out at any time.

Information Collection and Use
The Dana-Farber Waldenstrom's Macroglobulinemia Program is the sole owner of the personal medical information collected on this site. We will not sell, share, or rent this information to others. The Dana-Farber occasionally trades its contributor mailing lists with other non-profit organizations. This process saves us money and is carefully monitored and one may always opt-out.

Donations on the Web
When you make a gift on our site, your e-mail will be entered into our donor database. We may send you e-mails or mailings in the future informing you of other giving opportunities or providing news about The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia. If you choose not to receive any further communication from us, you may opt-out by e-mailing This email address is being protected from spambots. You need JavaScript enabled to view it. or calling our offices at 1-617-632-6285.

Latest Bing Center News

29th Annual IWMF Educational Forum

29th Annual IWMF Educational Forum

Join us May 3-5, 2024, at the Hyatt Regency in Renton, Washington for the 2024 Ed Forum. Renton, Washington is a lively suburb of Seattle and nestled on the southeast shore of Lake Washington. The Hyatt Regency and Lake Washington provide a picturesque backdrop to support education and engagement for the WM community.

Read more..

A Cure in Sight for Waldenstrom's Macroglobulinemia

A Cure in Sight for Waldenstrom's Macroglobulinemia

Dr. Steven Treon explains how recent advances in understanding the genomics and biology of Waldenstrom's macroglobulinemia make him hopeful and optimistic about a cure.

Read more..

Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, institute physician, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses preliminary data from a phase 2 study (NCT05065554) of acalabrutinib (Calquence) plus rituximab (Rituxan) in patients with Waldenström’s Macroglobulinemia or IgM symptomatic anti-myelin associated glycoprotein (MAG)–mediated peripheral neuropathy.

Read more..

Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, institute physician, Dana-Farber Cancer Institute, associate professor, medicine, Harvard Medical School, discusses the efficacy of treatment with iopofosine I 131 (previously CLR 131) in patients with Waldenström macroglobulinemia.

Read more..

Waldenstrom Macroglobulinemia: Who Gets What and When?

Waldenstrom Macroglobulinemia: Who Gets What and When?

As many as 50% of people at the time of their Waldenstrom macroglobulinemia (WM) diagnosis won’t need drug therapy for a number of years. We spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what “supportive treatments” could help in the meantime.

Read more..

In Memoriam of Dr. Enrica Morra

In Memoriam of Dr. Enrica Morra

Dear Members of the Waldenstrom’s Macroglobulinemia Community: I wanted to share with you the sad news that our colleague and friend, Dr. Enrica Morra recently passed away. Dr. Morra was the Co-Chair of 6th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM) which was held in Venice, Italy (2010), and a recipient of the Jan Gosta Waldenstrom Award for Lifetime Contributions to Waldenstrom’s Macroglobulinemia at the 8th IWWM in London, UK (2014).

Read more..

ASH-2023 Posters Presented

ASH-2023 Posters Presented

The following posters were presented by the Bing Center at the ASH 2023 meeting, December 9-12, 2023 in San Diego. For more information about the ASH 2023 meeting, please visit https://www.hematology.org/meetings/annual-meeting.

Read more..

ASH 2023 - Bing Center Abstracts to be Presented

ASH 2023 - Bing Center Abstracts to be Presented

The following abstracts represent the research that will be presented by the Bing Center at the ASH 2023 meeting, December 9-12, 2023 in San Diego. For more information about the ASH 2023 meeting, please visit https://www.hematology.org/meetings/annual-meeting.

Read more..

Waldenstrom: Reaching the Relapsed Refractory Stage

Waldenstrom: Reaching the Relapsed Refractory Stage

Waldenstrom Macroglobulinemia (WM) is not curable, which means most patients will either reach the relapsed or refractory stage at some point in their journey. Patient Power spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what reaching these stages mean for WM patients.

Read more..

Waldenstrom Macroglobulinemia: Who Gets What and When?

Waldenstrom Macroglobulinemia: Who Gets What and When?

As many as 50% of people at the time of their Waldenstrom macroglobulinemia (WM) diagnosis won’t need drug therapy for a number of years. We spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what “supportive treatments” could help in the meantime.

Read more..